About Us

Innoland, where Innovations Land

Innoland Biosciences is headquartered in Hangzhou. InnolandBio (Suzhou) was founded in 2021 and is mainly engaged in pre-clinical CRO service. The predecessor of InnolandBio (Suzhou) was the Cardiovascular and Metabolic Diseases Department of CrownBio Ltd. The very same team has 12 years of experience in pre-clinical pharmacological efficacy and toxicological evaluation, especially in the field of cardiovascular and metabolic diseases, and has been well recognized by world-renowned pharmaceutical companies. InnolandBio (Suzhou) now has the world’s largest cohort of non-human primates with spontaneous diabetes, and has established various animal models of diabetes complications, eye diseases and aging related diseases, etc. InnolandBio is dedicated to continuously provide high quality service to the global pharmaceutical research and development.